25-Sep-2026
MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Globe Newswire (Wed, 9-Sep 4:05 PM ET)
Globe Newswire (Thu, 13-Aug 4:05 PM ET)
Globe Newswire (Tue, 11-Aug 4:05 PM ET)
MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026
Globe Newswire (Thu, 23-Jul 4:01 PM ET)
MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals
Globe Newswire (Thu, 2-Jul 9:25 AM ET)
MGNX Secures $122.5 Million in Upfront Capital with Manufacturing Sale to Bora Pharmaceuticals
Market Chameleon (Tue, 12-May 6:33 AM ET)
Market Chameleon (Tue, 10-Mar 7:17 AM ET)
Market Chameleon (Thu, 13-Nov 5:38 AM ET)
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
Macrogenics trades on the NASDAQ stock market under the symbol MGNX.
As of September 25, 2026, MGNX stock price declined to $3.74 with 583,714 million shares trading.
MGNX has a beta of 0.62, meaning it tends to be less sensitive to market movements. MGNX has a correlation of 0.01 to the broad based SPY ETF.
MGNX has a market cap of $238.24 million. This is considered a Small Cap stock.
Last quarter Macrogenics reported $33 million in Revenue and -$.27 earnings per share. This fell short of revenue expectation by $-23 million and missed earnings estimates by -$.41.
In the last 3 years, MGNX traded as high as $21.88 and as low as $.99.
The top ETF exchange traded funds that MGNX belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
MGNX has outperformed the market in the last year with a return of +126.7%, while the SPY ETF gained +18.4%. However, in the most recent history, MGNX shares have underperformed the stock market with its stock returning -19.7% in the last 3 month period and -6.5% for the last 2 week period, while SPY has returned +5.3% and +1.2%, respectively.
MGNX support price is $3.66 and resistance is $3.94 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MGNX shares will trade within this expected range on the day.
